Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (113)	5/23/2008 7:24:35 AM
From: kenhott	Read Replies (2) \| Respond to of 139

<Causing another reiteration by Aschoff.> Me and Aschoff are buddies. The oral results are not that vague but has to be put in terms of Wyeth-ese. They have another oral formulation that will have results in the next 3ish months. I have to say that I am JUST a little confused about the progress of the oral trials. I guess they will look to see which one of the two formulations to take to phase 3. The completed oral had n~120, 5 arms with a placebo, so 20ish per arm. So showing stat.sign. in an arm or three is pretty good. Or quoting the PR: ... showed statistically significant activity as assessed by the occurrence of spontaneous bowel movements and other efficacy measures. <Suspect the overall market is about to do something violent, and not in a good way.> Trying to change your handle to Texasdude?? Just kidding.